MiniMed to announce financial results for its fourth quarter and full fiscal year 2026
MiniMed (Nasdaq: MMED) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiniMed (Nasdaq: MMED) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. A news release will be issued at ~3:45 a.m. PDT and a webcast will follow at 5:45 a.m. PDT.
According to MiniMed, the fiscal year ends on April 24, 2026, and a replay and transcript will be posted within 24 hours at the company investor site.
Details
News Market Reaction – MMED
On Apr 14, the first trading day after this news, MMED closed 5.70% above the previous close.
Data tracked by StockTitan Argus for the Apr 14 session.
Key Figures
- Earnings date
- June 3, 2026
- Scheduled Q4 and FY 2026 financial results release
- News release time
- 3:45 a.m. PDT
- Planned time for earnings press release on June 3, 2026
- Webcast time
- 5:45 a.m. PDT
- Scheduled webcast to discuss Q4 and FY 2026 results
- Fiscal year end date
- April 24, 2026
- End of MiniMed’s full fiscal year 2026
- Webcast replay window
- 24 hours
- Replay and transcript expected within 24 hours of webcast
Historical Context
-
FDA cleared MiniMed Flex™ insulin pump with strong real‑world Time in Range data.
-
Closing of IPO with 28M shares at $20 and ~$538M in net proceeds.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MiniMed will host a webcast at 5:45 a.m. PDT on June 3, 2026, to discuss results for its fourth quarter and full fiscal year 2026. The webcast can be accessed at https://investors.minimed.com.
Within 24 hours of the webcast, a replay and transcript of the prepared remarks will be available by clicking on the Events link at https://investors.minimed.com.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-announce-financial-results-for-its-fourth-quarter-and-full-fiscal-year-2026-302740889.html
SOURCE MiniMed
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.